A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Investigational new drugs

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10637-010-9529-9PMID 20820909
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

  2009influential reference
• Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation.

  2008cited by this paper
• Phase I (3 hour infusion every 3 weeks) escalating dose study of intravenous ES-285 in patients with advanced malignant solid tumors

  2007cited by this paper
• The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway

  2007cited by this paper
• Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices.

  2006cited by this paper
• Kahalalide F and ES285: potent anticancer agents from marine molluscs.

  2006cited by this paper
• Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl.

  2005cited by this paper
• ES-285, a novel marine anticancer agent: Investigation of mechanism of action using gene expression microarrays

  2005cited by this paper
• Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.

  2003cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000influential reference
• The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000influential reference

• A Review Discussing Synthesis and Translational Studies of Medicinal Agents Targeting Sphingolipid Pathways

  2025cites this paper
• Marine-Derived Anticancer Agents Targeting Apoptotic Pathways: Exploring the Depths for Novel Cancer Therapies

  2024cites this paper
• Homospisulosine induced apoptosis in cervical carcinoma cells is associated with phosphorylation of Bcl-2 and up-regulation of p27/Kip1.

  2023cites this paper
• Antiproliferative, Antioxidant, Chemopreventive and Antiangiogenic Potential of Chromatographic Fractions from Anemonia sulcata with and without Its Symbiont Symbiodinium in Colorectal Cancer Therapy

  2023cites this paper
• 1-Deoxysphingolipids and Their Analogs in Foods: The Occurrence and Potential Impact on Human Health.

  2022cites this paper
• 1-Deoxysphingolipids Tempt Autophagy Resulting in Lysosomal Lipid Substrate Accumulation: Tracing the Impact of 1-Deoxysphingolipids on Ultra-Structural Level using a Novel Click-Chemistry Detection

  2021cites this paper
• New Spisulosine Derivative promotes robust autophagic response to cancer cells.

  2020cites this paper
• Self-assembling nanoparticles of dually hydrophobic prodrugs constructed from camptothecin analogue for cancer therapy.

  2020cites this paper
• Natural products against cancer: Review on phytochemicals from marine sources in preventing cancer

  2019cites this paper
• Quantifying 1-deoxydihydroceramides and 1-deoxyceramides in mouse nervous system tissue.

  2019cites this paper
• Highlights of Natural Products in Prostate Cancer Drug Discovery

  2019influential citation
• 21 Highlights of Natural Products in Prostate Cancer Drug Discovery

  2018influential citation
• Localization of 1-deoxysphingolipids to mitochondria induces mitochondrial dysfunction[S]

  2016cites this paper
• Abbreviations: alkyne-doxSA: (2S,3R)-2-aminooctadec-17-yn-3-ol; alkyne-SA: (2S,3R)-2- aminooctadec-17-yn-1,3-diol; ASTM-BODIPY: azido-sulfo-tetramethyl-BODIPY; CE: cholesterolester; Cer: ceramide; CerS: ceramide synthase; DHCer; dihydroceramide; deoxySLs: 1-deoxysphingolipids; doxCer: 1-deoxyceramid

  2016cites this paper
• HSAN1 mutations in serine palmitoyltransferase reveal a close structure-function-phenotype relationship.

  2016cites this paper
• Ceramide as a Target of Marine Triterpene Glycosides for Treatment of Human Myeloid Leukemia

  2016cites this paper
• Marine Mollusk‐Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance

  2016cites this paper
• Identification and bioactivity of 3-epi-xestoaminol C isolated from the New Zealand brown alga Xiphophora chondrophylla.

  2014cites this paper
• Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

  2012cites this paper
• From the sea to anticancer therapy.

  2011cites this paper
• Highlights of natural compounds in prostate cancer drug discovery

  2011cites this paper
• Sphingolipid and Glycosphingolipid Metabolic Pathways in the Era of Sphingolipidomics

  2011cites this paper
• Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies

  2011cites this paper